Kymera Therapeutics, Inc.
NASDAQ:KYMRBiotechnology
+$1.50 today
- Market cap
- $10.34B
- Beta
- 2.03
- P/E (TTM)
- -28.3
- EPS (TTM)
- -$3.23
Volume 0.68M
Average 0.58M
KYMR Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Kymera Therapeutics, Inc.NASDAQ: KYMR
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income dips below year-ago levels
Q2 FY2026 net income of $61.21M (cash outflow) fell 20.1% year over year, behind the +8.8% change in trailing-twelve-month net income. Sequentially, it fell 11.6% from the prior quarter. Over 3 fiscal years it compounded at +26.2% a year.
Context
- Net income amounted to 794.3% of revenue in FY2025, up 318.7 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 17 analysts of -$317.21M (+1.9%) for the fiscal year ending Dec 2026, a slowdown from the +39.1% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$61.21M-11.6% QoQ
- Last fiscal yearDec 2025
- -$311.35M+39.1% YoY
- LTMJun 2026
- -$299.6M+8.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -20.1% | +54.1% | +74.2 pp |
| 1 year | +39.1% | +1.9% | -37.2 pp |
| 3-year CAGR | +26.2% | +24.2% | -2.0 pp |
| 5-year CAGR | +6.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (311.35M) USD
- Year-over-year change
- -39.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (311.35M) | -39.1% |
| FY2024 | 2024-12-31 | (223.86M) | -52.3% |
| FY2023 | 2023-12-31 | (146.96M) | +5.1% |
| FY2022 | 2022-12-31 | (154.81M) | -54.5% |
| FY2021 | 2021-12-31 | (100.22M) | — |
Net Income vs competitors
How KYMR compares with its peers on the latest reported figures
- KYMR's LTM Jun 2026 net income of $299.6M is the largest of the 5 companies compared; the peer median is $116.91M.
- Its year-over-year change of +8.8% is the 3rd highest of 5, against a peer median of +110.5%.
- Net income amounts to 285.4% of revenue for KYMR, versus a peer median of 272.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $299.6M | +8.8% | +26.2% | 285.4% | |
| LTM Aug 2026 | $294.88M | +220.5% | +13.6% | 42.0% | |
| LTM Mar 2026 | $221.3M | +374.9% | -34.1% | 247.5% | |
| LTM Mar 2026 | $130.01M | -2213.0% | -29.1% | 302.7% | |
| LTM Mar 2026 | $103.8M | +0.5% | -6.4% | 297.8% | |
| Peer median (excluding KYMR) | $116.91M | +110.5% | -17.8% | 272.6% | |
Competitors are the stored peer set for KYMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (100.22M) | (154.81M) | (146.96M) | (223.86M) | (311.35M) |
| Depreciation & Amortization | 2.4M | 2.98M | 3.57M | 7.37M | 8.31M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 24.97M | 35.48M | 43.12M | 55.01M | 59.9M |
| Change in Working Capital | (61.92M) | (37.62M) | 9.25M | (23.97M) | 15.27M |
| Accounts Receivables | 577K | (2.4M) | (16.23M) | 17.82M | 947K |
| Inventory | 8.71M | 2.4M | 0 | 0 | 0 |
| Accounts Payables | 54K | 253K | 0 | (307K) | (1.97M) |
| Other Working Capital | (71.26M) | (37.88M) | 25.48M | (41.48M) | 16.29M |
| Other Non-Cash Items | 5.83M | 889K | (11.8M) | (9.06M) | (5.02M) |
| Operating Cash Flow | (128.95M) | (153.09M) | (102.83M) | (194.5M) | (232.89M) |
| Capital Expenditures | (1.6M) | (2.84M) | (34.48M) | (12.84M) | (1.45M) |
| Acquisitions (Net) | 5.81M | (20.52M) | 0 | 0 | 0 |
| Purchases of Investments | (456.4M) | (445.97M) | 0 | (901.23M) | (1.01B) |
| Sales of Investments | 358.17M | 469.33M | 0 | 496M | 479.14M |
| Other Investing Activities | (5.81M) | 20.52M | 174.37M | 13.98M | 8.88M |
| Investing Cash Flow | (99.84M) | 20.52M | 139.89M | (404.08M) | (521.06M) |
| Debt Repayment | (849K) | (1.13M) | (76K) | (1.58M) | (1.49M) |
| Common Stock Issued | 243.11M | 149.83M | 0 | 596.62M | 992.21M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 8.02M | 4.3M | 4.27M | 13.81M | 0 |
| Financing Cash Flow | 250.28M | 153M | 4.19M | 608.85M | 990.71M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 21.5M | 20.43M | 41.25M | 10.27M | 236.76M |
| Free Cash Flow | (130.54M) | (155.92M) | (137.31M) | (207.34M) | (234.34M) |
Kymera Therapeutics, Inc.
NASDAQ:KYMR
Intrinsic Alpha fair value
Locked
Current Price
$121.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.